The highly aggressive nature of glioblastoma (GBM) leads to a dismal prognosis, and alternative therapies are being sought. Immunotherapy, such as the Dendritic Cell (DC) vaccine, is currently being evaluated for recurrent GBMs in clinical trials. Follow-up imaging after this immunotherapeutic approach often mimics disease progression on conventional images, making standard MRI evaluation challenging. Our findings indicate that our previously established multiparametric MRI-based prediction model has the capacity to accurately assess response to DC vaccine in recurrent GBM patients, objectively characterizing as either TP or PsP GBM patients, avoiding interruptions in satisfactory treatments, and preventing invasive procedures in PsP cases.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords